Lifecore Biomedical, Inc. (LFCR) income statement
LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
Số liệu tài chính tới Q4 năm tài chính 2025, quý kết thúc ngày May 25, 2025Last filing: 10-Q on Nov 4, 2026Score 4/30
$6.40+0.01 (+0.16%)
Close on Nov 18, 2026Market cap $242.26MP/E –Yield –
Lifecore Biomedical, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 31.3%
- Operating margin
- -13.4%
- Net margin
- -30.0%
- Return on equity, FY2025
- -612.1%
Financial strength
- Current ratio
- 3.87
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 79.7%
Valuation
- P/E ratio
- –
- Price to sales
- 1.88
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?